Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)
07. November 2019 07:00 ET
|
Arch Biopartners
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
22. August 2019 12:24 ET
|
Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....
Arch Biopartners Announces Start of Phase I Human Trial for Metablok
19. Juni 2019 07:20 ET
|
Arch Biopartners
TORONTO, June 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for...
Arch Biopartners Closes Convertible Note Financing
22. Mai 2019 17:01 ET
|
Arch Biopartners
TORONTO, May 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
Arch Biopartners Arranges Convertible Note Financing
17. Mai 2019 07:00 ET
|
Arch Biopartners
TORONTO, May 17, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
UPDATE - Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia
19. März 2019 10:06 ET
|
Arch Biopartners
TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred...
Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia
19. März 2019 08:46 ET
|
Arch Biopartners
TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred...
Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program
07. Februar 2019 08:00 ET
|
Arch Biopartners
TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial...
Arch Biopartners Closes Convertible Note Financing
29. Januar 2019 08:46 ET
|
Arch Biopartners
TORONTO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
Arch Biopartners Arranges Convertible Note Financing
24. Januar 2019 08:43 ET
|
Arch Biopartners
TORONTO, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...